Want to see TSE:BLO full AI Analyst Report?
Top Page
Cannabix Technologies
(BLO)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.48
▼(-5.88% Downside)
Action:Upgraded
Date:10/22/26
The score is primarily constrained by very weak financial performance (minimal revenue, persistent losses, and ongoing cash burn with equity erosion). Technicals provide a partial offset via short-term strength above key near-term moving averages, but the longer-term trend and MACD remain unfavorable. Valuation is also a headwind because the company is loss-making (negative P/E) and has no indicated dividend yield support.
Positive Factors
Low Leverage
Modest leverage reduces solvency pressure and gives the company more financial flexibility than a heavily indebted operation. Although the capital base is weakening, low debt exposure limits interest and refinancing burdens while management develops the company’s technology.
Negative Factors
Minimal Revenue and Persistent Losses
The company has not demonstrated meaningful revenue generation, while losses remain sizable and volatile. This indicates that the operating model has yet to cover its costs, leaving future progress dependent on successful commercialization rather than an established stream of recurring business income.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Modest leverage reduces solvency pressure and gives the company more financial flexibility than a heavily indebted operation. Although the capital base is weakening, low debt exposure limits interest and refinancing burdens while management develops the company’s technology.
Read all positive factors
Cannabix Technologies (BLO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$59.13M
Dividend YieldN/A
Average Volume (3M)38.82K
Price to Earnings (P/E)―
Beta (1Y)-0.15
Revenue GrowthN/A
EPS Growth-84.43%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryOther Precious Metals
Share Statistics
EPS (TTM)-0.03
Shares Outstanding123,177,765
10 Day Avg. Volume45,585
30 Day Avg. Volume38,816
Financial Highlights & Ratios
PEG Ratio-0.86
Price to Book (P/B)48.76
Price to Sales (P/S)0.00
P/FCF Ratio-50.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cannabix Technologies Business Overview & Revenue Model
Company Description
Cannabix Technologies Inc., a technology company, develops marijuana and alcohol breathalyzer technologies for employers, law enforcement, workplaces, and laboratories in the United States. It offers Cannabix Marijuana Breath Test (MBT) for Tetrah...
Cannabix Technologies Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -172.97K | -168.52K | -153.24K | -126.29K | -29.22K |
| EBITDA | -5.83M | -4.42M | -2.96M | -2.01M | -3.11M |
| Net Income | -5.76M | -4.69M | -3.13M | -2.14M | -3.37M |
Balance Sheet | |||||
| Total Assets | 2.21M | 3.00M | 4.70M | 6.95M | 8.76M |
| Cash, Cash Equivalents and Short-Term Investments | 1.59M | 2.35M | 4.26M | 6.52M | 8.45M |
| Total Debt | 160.06K | 158.65K | 154.58K | 132.54K | 0.00 |
| Total Liabilities | 431.71K | 447.71K | 248.02K | 237.17K | 120.84K |
| Stockholders Equity | 1.78M | 2.55M | 4.45M | 6.71M | 8.64M |
Cash Flow | |||||
| Free Cash Flow | -1.74M | -1.86M | -2.11M | -2.00M | -2.13M |
| Operating Cash Flow | -1.74M | -1.84M | -2.08M | -1.97M | -2.13M |
| Investing Cash Flow | 0.00 | -17.54K | -30.96K | -28.65K | -4.59K |
| Financing Cash Flow | 968.26K | -58.47K | -143.53K | 10.88K | 492.50K |
Cannabix Technologies Technical Analysis
Positive
0.51
Price Trends
0.42
Positive
0.49
Positive
0.57
Negative
Market Momentum
0.01
Negative
68.97
Neutral
89.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Positive. The current price of 0.51 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.42, and below the 200-day MA of 0.57, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 68.97 is Neutral, neither overbought nor oversold. The STOCH value of 89.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLO.
Cannabix Technologies Peers Comparison
UnderperformOutperform
Sector (51)
TSE:BLO
Cannabix Technologies
0.48
-0.04
-7.69%
TSE:PINK
Perimeter Medical Imaging AI
0.16
-0.11
-41.51%
TSE:VPT
VentriPoint Diagnostics
0.09
-0.02
-15.00%
Cannabix Technologies Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cannabix launches DOT-like breath-based multi-drug test panel for recent-use detection
Positive
Oct 20, 2026
Cannabix Technologies Inc., a Vancouver-based developer of breath-based marijuana and alcohol testing solutions, focuses on non-invasive tools that enhance public and workplace safety by identifying recent impairment rather than historical drug us...
Business Operations and StrategyProduct-Related Announcements
Cannabix Files Patent for Rapid Point-of-Care Marijuana Breath Test
Positive
Oct 14, 2026
Cannabix Technologies has filed a U.S. provisional patent application for a rapid, point-of-care marijuana breath test that combines its proprietary Breath Collection Unit and Breath Cartridge with lateral flow assay platforms. The proposed system...
Business Operations and StrategyProduct-Related Announcements
Cannabix’s BreathLogix Enters U.S. Manufacturing Market with Alabama Deployment
Positive
Sep 29, 2026
Cannabix Technologies has deployed its BreathLogix alcohol screening solution at a manufacturing facility in Alabama, marking the product’s first delivery to a U.S.-based manufacturing company. The system, distributed through reseller AlcoPr...
Business Operations and StrategyProduct-Related Announcements
Cannabix Expands BreathLogix Alcohol Monitoring Deployment in Montana
Positive
Aug 21, 2026
Cannabix Technologies has deployed its BreathLogix alcohol screening system at the Big Horn County Misdemeanor Probation and Pre-trial Services department in Montana, expanding its footprint under the state’s 24/7 Sobriety Program. The devic...
Business Operations and StrategyProduct-Related Announcements
Cannabix Targets Combat Sports for Marijuana Breath Test Rollout
Positive
Aug 5, 2026
Cannabix Technologies Inc., listed on the CSE, OTC and Frankfurt exchanges, develops marijuana and alcohol breath-testing technologies aimed at workplace and public safety markets. Its flagship Marijuana Breath Test targets recent THC use through ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.